Immunotherapy by gene transfer with plasmids encoding IL-12/IL-18 is superior to IL-23/IL-18 gene transfer in a rat osteosarcoma model

Anticancer Research

Volumn 24, Issue 5 A, 2004, Pages 2861-2867

  Liebau, Christian ^a   Roesel, Christian ^c   Schmidt, Sebastian ^a   Karreman, Christiaan ^c   Prisack, Johannes Bernd ^c   Bojar, Hans ^c   Merk, Harry ^a   Wolfram, Neumann ^d   Baltzer, Axel W A ^b  

^a Asklepios Clinic   (Germany)

^b Centre for Molecular Orthopaedics   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Gene therapy; IL 12; IL 18; IL 23; Immunotherapy; Osteosarcoma

Indexed keywords

CYTOKINE; ENZYME; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 23; INTERLEUKIN CONVERTING ENZYME; PROINTERLEUKIN 18; RECOMBINANT INTERLEUKIN 18; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL STRAIN UMR 108; CYTOKINE RELEASE; CYTOTOXICITY; GENE TRANSFER; GENETIC TRANSFECTION; MALIGNANT NEOPLASTIC DISEASE; MESENCHYME CELL; MONONUCLEAR CELL; NONHUMAN; OSTEOSARCOMA; PLASMID; PRIORITY JOURNAL; RAT; TUMOR IMMUNITY;

ANIMALS; BONE NEOPLASMS; CASPASE 1; CELL LINE, TUMOR; GENE THERAPY; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-18; INTERLEUKIN-23; INTERLEUKIN-23 SUBUNIT P19; INTERLEUKINS; OSTEOSARCOMA; PLASMIDS; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFECTION;

EID: 6444226708     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Link MP, Goorin AM, Miser AW et al: The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314: 1600-6, 1986.
2. Kuida K, Lippke JA, Ku G et al: Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science 267: 2000-3, 1995.
3. Zheng H, Fletcher D, Kozak W et al: Resistance to fever induction and impaired acute-phase response in interleukin-1 beta-deficient mice. Immunity 3: 9-19, 1995.
4. Brunda MJ, Luistro L, Hendrzak JA, Fountoulakis M, Garotta G and Gately MK: Role of interferon-gamma in mediating the antitumor efficacy of interleukin-12. J Immunother Emphasis Tumor Immunol 17: 71-77, 1995.
5. Brunda MJ, Luistro L, Rumennik L et al: Interleukin-12: murine models of a potent antitumor agent. Ann N Y Acad Sci 31: 266-74, 1996.
6. Gately MK, Renzetti LM, Magram J et al: The interleukin-12/interleukin- 12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol 16: 495-521, 1998.
7. Gubler U, Chua AO, Schoenhaut DS et al: Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc Natl Acad Sci USA 88: 4143-7, 1991.
8. Okamura H, Tsutsi H, Komatsu T et al: Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378: 88-91, 1995.
9. Tanaka F, Hashimoto W, Okamura H, Robbins PD, Lotze MT and Tahara H: Rapid generation of potent and tumor-specific cytotoxic T-lymphocytes by interleukin 18 using dentritic cells and natural killer cells. Cancer Res 60: 4838-4844, 2000.
10. Ushio S, Namba M, Okura T et al: Cloning of the cDNA for human IFN-gamma-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. J Immunol 156: 4274-4279, 1996.
11. olf SF, Temple PA, Kobayashi M et al: Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 146: 3074-3081, 1991.
12. Brunda MJ, Luistro L, Warrier RR et al: Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178: 1223-30, 1993.
13. Osaki T, Peron JM, Cai Q et al: IFN-gamrna-inducing factor/IL-18 administration mediates IFN-gamma and IL-12-independent antitumor effects. J Immunol 160: 1742-1749, 1998.
14. Yamanaka K, Kara I, Nagai H et al: Synergistic antitumor effects of interleukin-12 gene transfer and systemic administration of interleukin-18 in a mouse bladder cancer model. Cancer Immunol Immunother 48: 297-302, 1999.
15. Boehm U, Klamp T, Groot M and Howard JC: Cellular responses to interferon-gamma. Annu Rev Immunol 15: 749-95, 1997.
16. Xie QW, Whisnant R and Nathan C: Promoter of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility by interferon gamma and bacterial lipopolysaccharide. J Exp Med 177: 1779-84, 1993.
17. Worth LL, Jia SF, Zhou Z, Chen L and Kleinerman ES: Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases. Clin Cancer Res 6: 3713-3718, 2000.
18. Rakhmilevich AL, Turner J, Ford MJ et al: Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc Natl Acad Sci USA 93: 6291-6296, 1996.
19. Oppmann B, Lesley R, Blom B et al: Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13: 715-25, 2000.
20. Ushio S, Namba M, Okura T et al: Cloning of the cDNA for human IFN-gamma-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. J Immunol 156: 4274-9, 1996.
21. Okamura H, Tsutsui H, Kashiwamura S, Yoshimoto T and Nakanishi K: Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Adv Immunol 70: 281-312, 1998.
22. Okamura H, Nagata K, Komatsu T et al: A novel costimulatory factor for gamma Interferon induction found in the livers of mice causes endotoxic shock. Infect Immun 63: 3966-72, 1995.
23. Kohno K, Kataoka J, Ohtsuki T et al: IFN-gamma-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. J Immunol 158: 1541-50, 1997.
24. Dao T, Ohashi K, Kayano T, Kurimoto M and Okamura H: Interferon-gamma- inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells. Cell Immunol 173: 230-5, 1996.
25. Tsutsui H, Nakanishi K, Matsui K et al: IFN-gamma-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. J Immunol 157: 3967-73, 1996.
26. Micallef MJ, Tanimoto T, Kohno K, Ikeda M and Kurimoto M: Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma. Cancer Res 57: 4557-63, 1997.
27. Micallef MJ, Yoshida K, Kawai S et al: In vivo antitumor effects of murine interferon-gamma-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites. Cancer Immunol Immunother 43: 361-7, 1997.
28. Ghayur T, Banerjee S, Hugunin M et al: Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature 386: 619-23, 2003.
29. Liebau C, Merk H, Roesel C et al: rIL-18 triggered gene therapy based on a transduction with the IL-12 plasmid: a new option as immuno-therapy for osteosarcoma? Anticancer Res 22: 2559-65, 2002.
30. Karreman S: Entwicklung von Strategien zur Expression von Genen in Säugetierzellinien durch gerichtete Integration. Dissertation, 1997.
31. Chen L, Chen D, Block E et al: Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer. J Immunol 159: 351-9, 1997.
32. Lafleur EA, Jia SF, Worth LL, Zhou Z, Owen-Schaub LB and Kleinerman ES: Interleukin (IL)-12 and IL-12 gene transfer upregulate Fas expression in human osteosarcoma and breast cancer cells. Cancer Res 61: 4066-71, 2001.
33. Atkins MB, Robertson MJ, Gordon M et al: Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 3: 409-17, 1997.
34. Cohen J: IL-12 deaths: explanation and a puzzle. Science 270: 908, 1997.
35. Ahn HJ, Maruo S, Tomura M et al: A mechanism underlying synergy between IL-12 and IFN-gamma-inducing factor in enhanced production of IFN-gamma. J Immunol 159: 2125-31, 1997.
36. Oshikawa K, Shi F, Rakhmilevich AL, Sondel PM, Mahvi DM and Yang NS: Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-12, pro-IL-18, and IL-1beta converting enzyme cDNA. Proc Natl Acad Sci USA 96: 13351-6, 1999.
37. Yoshimoto T, Takeda K, Tanaka T et al: IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J Immunol 161: 3400-7, 1998.
38. Xu D, Chan WL, Leung BP et al: Selective expression and functions of interleukin 18 receptor on T helper (Th) type 1 but not Th2 cells. J Exp Med 188: 1485-92, 1998.